Summary
One hundred and twelve post menopausal or post oophorectomy women with advanced breast cancer (BC) who had all previously had aminoglutethimide (AG) were treated with the potent aromatase inhibitor 4-hydroxy androstenedione (4-OHA).
Twenty three women (21%) had a partial response to 4-OHA while another twenty five patients (22%) had stabilization of previously progressing disease. Patients responded to 4-OHA both after previously responding to then relapsing on, and after failing to respond to aminoglutethimide. Toxicity was minimal. This study shows that potent aromatase inhibition with 4-OHA is effective in women with advanced BC who have already been treated with a less potent aromatase inhibitor, and suggests that relative changes in oestrogen levels may be more important than absolute levels.
This is a preview of subscription content, log in via an institution to check access.
References
Brodie AHM, Coombes RC, Dowsett M: Aromatase inhibitors: Basic and clinical studies. J Steroid Biochem 27: 899–903, 1987
Coombes RC, Hughes SWM, Dowsett M: 4-Hydroxy androstenedione: A new treatment for postmenopausal patients with breast cancer. Eur J Cancer 12: 1941–1945, 1992
Hoffken K, Jonat W, Possinger Ket al.: Aromatase inhibition with 4-hydroxy androstenedione in the treatment of postmenopausal patients with advanced breast cancer: A Phase II study. J Clin Oncol 8: 875–880, 1990
Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher E, Samojilk E, Wells SA: Aminoglutethimide as treatment of postmenopausal women with advanced breast cancer. Ann Intern Med 96: 94–101, 1982
Murray RML, Pitt P: Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment. Breast Cancer Research and Treatment 1: 91–95, 1981
Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M, Brodie AMH: 4-hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 50: 245–25, 1987
Smith I: First and second-generation aromatase inhibitors. In: Santen RJ, Juhos E (eds) Endocrine-dependent breast cancer: critical assessment of recent advances. Hans Huber, New York, 1986, pp 58–68
Dowsett M, Harris AI, Stewart-Harris R, Cantwell BMJ, Smith IE, Jeffcoate SL: A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in post menopausal breast cancer patients. Br J Cancer 52: 525–529, 1985
Lønning PE, Dowsett M, Jones A, Ekse D, Jacobs S, McNeil F, Johannessen DC, Powles TJ: Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Research and Treatment 23: 57–62, 1992
Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305: 545–51, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murray, R., Pitt, P. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Tr 35, 249–253 (1995). https://doi.org/10.1007/BF00665976
Issue Date:
DOI: https://doi.org/10.1007/BF00665976